Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Neuropathiazol (HB3105)
Description:Selective neuronal differentiation inducer in hippocampal neural progenitors
Purity:>98%
NS 309 (HB1049)
Description:Potent, selective KCa3.1 / KCa2 channel subfamily activator
Purity:>98%
±-Octopamine hydrochloride (HB2791)
Description:Invertebrate neurotransmitter. Chemogenetic DmOctβ1 receptor activator.
Purity:>99%
Perlapine (HB4889)
Description:Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator
Purity:>98%